Evidence map›Paper›PMID 36816924›Full record

ArticleFrontiers in oncology2023

T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations.

Elisavet Vlachonikola, Nikolaos Pechlivanis, Georgios Karakatsoulis, Electra Sofou, Glykeria Gkoliou, Sabine Jeromin, Niki Stavroyianni, Pamela Ranghetti, Lydia Scarfo, Cecilia Österholm and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. IMGTAntibodies (Basel, Switzerland) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 4 countries.

Elisavet VlachonikolaInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Nikolaos PechlivanisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Georgios KarakatsoulisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Electra SofouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Glykeria GkoliouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Sabine JerominMLL - Munich Leukemia Laboratory, Munich, Germany.
Niki StavroyianniHematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Pamela RanghettiDivision of Experimental Oncology, Università Vita-Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale San Raffaele, Milan, Italy.
Lydia ScarfoDivision of Experimental Oncology, Università Vita-Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale San Raffaele, Milan, Italy.
Cecilia ÖsterholmDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Larry MansouriDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Sofia NotopoulouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Alexandra SiorentaImmunology Department and National Tissue Typing Center, General Hospital of Athens "G. Gennimatas", Athens, Greece.
Achilles AnagnostopoulosHematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Paolo GhiaDivision of Experimental Oncology, Università Vita-Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale San Raffaele, Milan, Italy.
Claudia HaferlachMLL - Munich Leukemia Laboratory, Munich, Germany.
Richard RosenquistDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Fotis PsomopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Anastasia KouvatsiDepartment of Genetics, Development and Molecular Biology, School of Biology, Aristotle, University of Thessaloniki, Thessaloniki, Greece.
Panagiotis BaliakasDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Anastasia ChatzidimitriouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRKarolinska Institutet · SEVita-Salute San Raffaele University · ITCentre for Research and Technology Hellas · GRG. Papanikolaou General Hospital · GRMunich Leukemia Laboratory (Germany) · DEDemocritus University of Thrace · GRGeneral Hospital of Athens G. Genimatas · GRKarolinska University Hospital · SEUniversity of Ioannina · GRUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Microenvironmental interactions of the malignant clone with T cells are critical throughout the natural history of chronic lymphocytic leukemia (CLL). Indeed, clonal expansions of T cells and shared clonotypes exist between different CLL patients, strongly implying clonal selection by antigens. Moreover, immunogenic neoepitopes have been isolated from the clonotypic B cell receptor immunoglobulin sequences, offering a rationale for immunotherapeutic approaches. Here, we interrogated the T cell receptor (TR) gene repertoire of CLL patients with different genomic aberration profiles aiming to identify unique signatures that would point towards an additional source of immunogenic neoepitopes for T cells. Experimental design: TR gene repertoire profiling using next generation sequencing in groups of patients with CLL carrying one of the following copy-number aberrations (CNAs): del(11q), del(17p), del(13q), trisomy 12, or gene mutations in Results: Oligoclonal expansions were found in all patients with distinct recurrent genomic aberrations; these were more pronounced in cases bearing CNAs, particularly trisomy 12, rather than gene mutations. Shared clonotypes were found both within and across groups, which appeared to be CLL-biased based on extensive comparisons against TR databases from various entities. Moreover, Conclusions: Distinct TR repertoire profiles were identified in groups of patients with CLL bearing different genomic aberrations, alluding to distinct selection processes. Abnormal protein expression and gene dosage effects associated with recurrent genomic aberrations likely represent a relevant source of CLL-specific selecting antigens.

Indexed as

chronic lymphocytic leukemia (CLL)neoepitopesrecurrent genomic aberrationsT cell based immunotherapiesT cell receptor (TR) gene repertoire

Identifiers

PMID36816924
PMCPMC9929157
OpenAlexW4318822451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.